CD45RB Antibody PE Conjugate, Clone: [BRA-11], Mouse, Monoclonal

Produktübersicht

• Artikelname: CD45RB Antibody PE Conjugate, Clone: [BRA-11], Mouse, Monoclonal
• Artikelnummer: NSJ-V2245PE-100T
• Hersteller Artikelnummer: V2245PE-100T
• Alternativnummer: NSJ-V2245PE-100T
• Hersteller: NSJ Bioreagents
• Wirt: Mouse
• Kategorie: Antikörper
• Applikation: FACS
• Spezies Reaktivität: Human
• Immunogen: The non-T, non-B CALLA positive ALL cell line REH (Leucocyte Workshop IV and V) was used as the immunogen for this antibody.
• Konjugation: PE

Produktbeschreibung

CD45R, also designated CD45 and PTPRC, has been identified as a transmembrane glycoprotein, broadly expressed among hematopoietic cells. Multiple isoforms of CD45R are distributed throughout the immune system according to cell type. These isoforms arise because of alternative splicing of exons 4, 5, and 6. The corresponding protein domains are characterized by the binding of monoclonal antibodies specific for CD45RA (exon 4), CD45RB (exon 5), CD45RC (exon 6) and CD45RO (exons 4 to 6 spliced out). The variation in these isoforms is localized to the extracellular domain of CD45R, while the intracellular domain is conserved. CD45R functions as a phosphor-tyrosine phosphatase. antibody to CD45R is useful in differential diagnosis of lymphoid tumors from non-hematopoietic undifferentiated neoplasms.

Produkteigenschaften

• Klonalität: Monoclonal
• Konzentration: 500 ul at 0.1 mg/ml with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide
• Klon-Bezeichnung: [BRA-11]
• Isotyp: Mouse IgG1, kappa
• NCBI: 5788
• Puffer: 500 ul at 0.1 mg/ml with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide
• Reinheit: Protein G affinity chromatography
• Formulierung: 500 ul at 0.1 mg/ml with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide
• Target-Kategorie: CD45RB
• Antibody Type: Primary Antibody

Anwendungsbeschreibung

• Application Verdünnung: Flow Cytometry: 5ul/test/10e6 cells in 100ul (or 5ul per 100ul of whole blood),Immunofluorescence: 1:50-1:100
• Anwendungsbeschreibung: The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the antibody to be titered up or down for optimal performance.